Share on StockTwits

MannKind (NASDAQ:MNKD) VP Juergen Martens sold 76,899 shares of the company’s stock on the open market in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $7.50, for a total transaction of $576,742.50. Following the sale, the vice president now directly owns 139,024 shares of the company’s stock, valued at approximately $1,042,680. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of MannKind (NASDAQ:MNKD) traded up 3.10% on Wednesday, hitting $7.805. The stock had a trading volume of 9,966,470 shares. MannKind has a 52-week low of $3.80 and a 52-week high of $8.70. The stock has a 50-day moving average of $6.48 and a 200-day moving average of $5.69. The company’s market cap is $2.950 billion.

MannKind (NASDAQ:MNKD) last announced its earnings results on Monday, May 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. During the same quarter in the previous year, the company posted ($0.15) earnings per share. On average, analysts predict that MannKind will post $-0.37 earnings per share for the current fiscal year.

MNKD has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of MannKind in a research note on Wednesday, May 14th. They now have a $7.00 price target on the stock. Separately, analysts at Piper Jaffray upgraded shares of MannKind from an “underweight” rating to a “neutral” rating in a research note on Wednesday, May 14th. They now have a $6.50 price target on the stock, up previously from $2.00. They noted that the move was a valuation call. Finally, analysts at MLV & Co
reiterated a “buy” rating on shares of MannKind in a research note on Tuesday, May 13th. They now have a $10.00 price target on the stock, down previously from $11.00. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $7.58.

MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.